Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids

doi:10.3748/wjg.v23.i31.5650

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 31

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13112)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

1881

WORD

280

HTML

6642

Tables (1-3)

326

Sum=9129

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

498

Download

1139

Sum=1637

Publishing Process of This Article

Item

Count

Browse

1013

Download

1333

Sum=2346

Aug 21, 2017 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (71)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Aug 21, 2017; 23(31): 5650-5668
Published online Aug 21, 2017. doi: 10.3748/wjg.v23.i31.5650

Table 3 Circulating cell-free microRNA in hepatocellular carcinoma

miR	Expression	Sample	HCC patients	Ethnicity	Background liver	Controls	Value	Ref.
miR-1	Up	Serum	195	Germany	HCV: 45%, Alcohol: 33%, HBV: 17%	54 (HD: 54)	P	Köberle et al[155] 2013
miR-10b	Up	Blood	27	China	Alcohol: 23%	81 (HD: 81)	D	Jiang et al[175] 2015
miR-15b	Up	Serum	153	China	HBV: 88%	59 (HD: 29, HV: 39)	D	Liu et al[152] 2012
miR-15b-5p	Down	Plasma	37	China	NA	60 (HD: 29, HV: 31)	D	Chen et al[170] 2015
miR-16	Down	Serum	105	United States	HCV: 64%, HBV: 20%	178 (HD: 107, HV: 7)	D	Qu et al[148] 2011
			90	China	NA	60 (HV: 60)	D	Ge et al[161] 2014
			40	Egypt	HCV: 100%	60 (HD: 40, HV: 20)	D	El-Abd et al[174] 2015
miR-17-5p	Up	Serum	136	China	NA	NA	P	Zheng et al[159] 2013
miR-17-5p	Up	Serum	8	Turkey	HCV: 100%	84 (HD: 56, HV: 28)	D	Oksuz et al[178] 2015
miR-18a	Up	Serum	101	China	HBV: 100%	90 (HD: 30, HV: 60)	D	Li et al[151] 2012
miR-18a	Up	Serum	20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
miR-19a	Down	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-21	Up	Plasma	457	China	HBV:100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
miR-21		Plasma	136	Japan	HCV:68%, HBV: 23%	80 (HD: 30, HV: 50)	D, P	Tomimaru et al[153] 2012
		Serum	101	China	HBV: 75%	137 (HD: 48, HV: 89)	D	Xu et al[149] 2011
			136	China	HBV: 95%	NA	P	Liu et al[164] 2014
			97	China	HBV: 62%	30 (HV: 30)	D, P	Wang et al[180] 2015
			23	Egypt	HCV: 87%, HBV: 13%	17 (HD: 17)	D	Amr et al[186] 2016
	Down	Serum	70	China	HBV: 100%	72 (HD 48, HV: 24)	D	Qi et al[147] 2011
			90	China	NA	60 (HV: 60)	D, P	Ge et al[161] 2014
			52	China	HBV: 63%, HCV: 4%	85 (HD: 42, HV: 43)	D	Zhuang et al[195] 2016
miR-22	Down	Serum	192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekri et al[194] 2016
miR-24-3p	Up	Serum	84	China	HBV: 100%	77 (HD: 31, HV: 46)	D, P	Meng et al[165] 2014
miR-26a	Down	Plasma	457	China	HBV: 100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
miR-26a	Down	Serum	52	China	HBV: 63%, HCV: 4%	85 (HD42, HV: 43)	D	Zhuang et al[195] 2016
miR-26a-5p	Down	Serum	261	China	HBV: 100%	406 (HD 233, HV: 173)	D	Tan et al[166] 2014
miR-27a	Down	Plasma	457	China	HBV: 100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
miR-29b	Down	Serum	192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekri et al[194] 2016
miR-30c	Down	Serum	242	China	HCV: 63%	NA	P	Liu et al[176] 2015
miR-30c-5p	Down	Serum	8	Turkey	HCV: 100%	84 (HD: 56, HV: 28)	D	Oksuz et al[178] 2015
miR-34a	Up	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-92a-3p	Up	Plasma	20	Turkey	HBV: 100%	74 (HD: 46, HV: 28)	D	Giray et al[162] 2014
miR-96	Up	Serum	104	China	HBV: 100%	400 (HD: 280, HV: 120)	D	Chen et al[171] 2015
miR-101	Up	Serum	25	China	HBV: 100%	20 (HV: 20)	D	Fu et al[154] 2013
	Down	Serum	67	China	HBV: 100%	170 (HD: 140, HV: 3,)	D	Xie et al[167] 2014
			20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
			52	China	HBV: 63%, HCV: 4%	85 (HD: 42, HV: 43)	D	Zhuang et al[195] 2016
miR-106b	Up	Blood	27	China	Alcohol: 23%	81 (HD: 31, HV: 50,)	D	Jiang et al[175] 2015
miR-122	Up	Serum	70	China	HBV: 100%	72 (HD: 48, HV: 24,)	D	Qi et al[147] 2011
			101	China	HBV: 75%	137 (HD: 48, HV: 89,)	D	Xu et al[149] 2011
			195	Germany	HCV: 45%, Alcohol: 33%, HBV: 17%	54 (HD: 54)	P	Köberle et al[155] 2013
			30	Egypt	HCV: 100%	70 (HD: 60, HV: 10)	D	El-Garem et al[160] 2014
			136	China	HBV: 95%	NA	P	Liu et al[164] 2014
			192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekri et al[194] 2016
	Down	Plasma	457	China	HBV: 100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
		Serum	20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
		Serum	122	China	NA	NA	P	Xu et al[181] 2015
miR-122a	Down	Serum	85	China	HBV: 88%	HV (HV: 85)	D	Luo et al[156] 2013
miR-122-5p	Up	Plasma	20	Turkey	HBV: 100%	74 (HD: 46, HV: 28)	D	Giray et al[162] 2014
		Plasma	120	South Korea	HBV: 100%	NA	P	Cho et al[172] 2015
		Serum	120	China	HBV: 100%	DN: 30	D	Hung et al[189] 2016
	Down	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
miR-125b	Down	Plasma	64	China	HBV: 100%	178 (HD: 122, HV: 56)	D	Chen et al[187] 2016
miR-125b-5p	Up	Plasma	20	Turkey	HBV: 100%	74 (HD: 46, HV: 28)	D	Giray et al[162] 2014
miR-126	Up	Plasma	59	India	HBV: 100%	38 (HD: 20, HV: 18)	D	Ghosh et al[188] 2016
miR-126	Down	Serum	23	Egypt	HCV: 100%	55 (HD: 55)	D	Khairy et al[190] 2016
miR-128-2	Up	Serum	222	China	HBV: 87%	NA	P	Zhuang et al[184] 2015
miR-129	Down	Serum	23	Egypt	HCV: 100%	55 (HD: 55)	D	Khairy et al[190] 2016
miR-130a	Up	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-130b	Up	Serum	153	China	HBV: 88%	59 (HD: 29, HV: 30)	D	Liu et al[152] 2012
miR-139	Down	Plasma	31	China	NA	31 (HD: 31)	D, P	Li et al[163] 2014
miR-141-3p	Up	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
miR-143	Up	Serum	95	China	NA	245 (HD: 118, HV: 127)	D	Zhang et al[168] 2014
miR-143-3p	Up	Plasma	59	India	HBV: 100%	38 (HD: 20, HV: 18)	D	Ghosh et al[188] 2016
miR-146a	Up	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-150	Down	Serum	120	China	HBV: 100%	230 (HD: 110, HV: 120)	D, P	Yu et al[183] 2015
miR-155	Down	Serum	23	Egypt	HCV: 100%	55 (HD: 55)	D	Khairy et al[190] 2016
miR-181a	Down	Blood	27	China	Alcohol: 23%	81 (HD: 31, HV: 50)	D	Jiang et al[75] 2015
miR-181b	Up	Serum	192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekr et al[194] 2016
miR-182	Up	Serum	103	China	NA	135 (HD: 95, HV: 40)	D, P	Chen et al[169] 2015
miR-192	Up	Plasma	457	China	HBV: 100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
miR-192	Up	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-192-5p	Down	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
miR-195	Down	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-195	Down	Serum	20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
miR-199a	Down	Serum	105	United States	HCV: 64%, HBV: 20%	178 (HD: 107, HV: 71)	D	Qu et al[148] 2011
			40	Egypt	HCV: 100%	60 (HD: 40, HV: 20)	D, P	El-Abd et al[174] 2015
			78	China	NA	156 (HV: 156)	D	Yin et al[182] 2015
			23	Egypt	HCV: 87%, HBV: 13%	17 (HD: 17)	D	Amr et al[186] 2016
miR-199a-3p	Down	Serum	192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekri et al[194] 2016
miR-199a-5p	Down	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
miR-200a	Up	Serum	136	China	HBV: 95%	NA	P	Liu et al[176] 2015
miR-203	Down	Serum	23	Egypt	HCV: 100%	55 (HD: 55)	D	Khairy et al[190] 2016
miR-203a	Down	Serum	242	China	HCV: 63%	NA	P	Liu et al[176] 2015
miR-206	Up	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
miR-215	Up	Serum	95	China	NA	245 (HD: 118, HV: 127)	D	Zhang et al[168] 2014
miR-218	Down	Serum	156	China	HBV: 72%	162 (HD: 98, HV: 64)	D, P	Yang et al[193] 2016
miR-221	Up	Serum	20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
	Up	Serum	192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekri et al[194] 2016
	Down	Serum	30	Egypt	HCV: 100%	70 (HD: 60, HV: 10)	D	El-Garem et al[174] 2014
miR-222	Up	Serum	70	China	HBV: 100%	72 (HD: 48, HV: 24)	D	Qi et al[147] 2011
miR-222	Up	Serum	20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
miR-223	Up	Serum	70	China	HBV: 100%	72 (HD: 48, HV: 24)		Qi et al[147] 2011
	Up	Serum	101	China	HBV: 75%	137 (HD: 48, HV: 89)	D	Xu et al[149] 2011
	Down	Plasma	457	China	HBV: 100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
	Down	Serum	23	Egypt	HCV: 100%	55 (HD: 55)	D	Khairy et al[190] 2016
miR-223-3p	Down	Plasma	20	Turkey	HBV: 100%	74 (HD: 46, HV: 28)	D	Giray et al[162] 2014
miR-223-3p	Down	Serum	8	Turkey	HCV: 100%	84 (HD: 56, HV: 28)	D	Oksuz et al[178] 2015
miR-224	Up	Plasma	107	Japan	HCV: 41%, HBV: 18%, Alcohol: 15%	102 (HD: 27, HV: 75)	D, P, T	Okajima et al[192] 2016
		Serum	20	South Korea	HBV: 70%	40 (HD: 40)	D	Sohn et al[179] 2015
			182	China	HBV: 87%	NA	D, P	Zhuang et al[185] 2015
			122	China	HBV: 100%	157 (HD: 135, HV: 22)	D	Lin et al[191] 2016
miR-224-5p	Up	Serum	136	China	HBV: 95%	NA	P	Liu et al[164] 2014
miR-296	Up	Serum	112	Egypt	HCV: 100%	167 (HD: 125, HV: 42)	D	Motawi et al[177] 2015
miR-302c-3p	Down	Serum	8	Turkey	HCV: 100%	84 (HD: 56, HV: 28,)	D	Oksuz et al[178] 2015
miR-331-3p	Up	Serum	103	China	NA	135 (HD: 95, HV: 40)	D, P	Chen et al[169] 2015
miR-335	Down	Serum	125	China	NA	250 (HD: 125, HV: 125)	D, P	Cui et al[173] 2015
miR-338-5p	Up	Plasma	37	China	NA	60 (HD: 29, HV: 31)	D	Chen et al[170] 2015
miR-375	Up	Serum	120	China	HBV: 100%	393 (HD: 183, HV: 210)	D	Li et al[145] 2010,
miR-375	Down	Serum	78	China	NA	156 (HV: 156)	D	Yin et al[182] 2015.
miR-433-3p	Up	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
miR-483-5p	Up	Serum	69	United States	HCV: 63%, HBV: 14%	69 (HV: 69)	D	Shen et al[157] 2013
miR-483-5p	Up	Serum	112	China	NA	141 (HD: 56, HV: 85)	D	Zhang et al[158] 2013
miR-500a	Up	Serum	112	China	NA	141 (HD: 56, HV: 85)	D	Zhang et al[158] 2013
miR-764	Up	Plasma	37	China	NA	60 (HD: 29, HV: 31)	D	Chen et al[170] 2015
miR-801	Up	Plasma	457	China	HBV: 100%	477 (HD: 310, HV: 167)	D	Zhou et al[150] 2011
miR-885-5p	Up	Serum	46	China	HBV: 72%	105 (HD: 64, HV: 24, GC: 17)	D	Gui et al[146] 2011
miR-885-5p	Up	Serum	192	Egypt	HCV: 100%	192 (HD: 192)	D	Zekri et al[194] 2016
miR-1228-5p	Up	Serum	261	China	HBV: 100%	406 (HD: 233, HV: 173)	D	Tan et al[166] 2014
let-7b	Up	Serum	120	China	HBV: 100%	30 (DN: 30)	D	Hung et al[189] 2016
let-7f	Down	Serum	90	China	NA	60 (HV: 60)	D, P	Ge et al[161] 2014

NA: Not applicable; HV: Healthy volunteers; HD: Hepatic disease without evidence of HCC; GC: Gastric cancer; DN: Dysplastic nodule; D: Diagnostic marker; P: Prognostic marker; T: Treatment outcome marker.

Citation: Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23(31): 5650-5668
URL: https://www.wjgnet.com/1007-9327/full/v23/i31/5650.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i31.5650